A Phase 1 interventional study of Elamipretide in Barth Syndrome, sponsored by Stealth BioTherapeutics Inc.. Not yet recruiting. Open to male participants. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Stealth BioTherapeutics Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This Phase 1, open-label trial will enroll approximately 6 subjects who have BTHS weighing between 7 and 30 kg. Subjects will receive a weight-based dose of elamipretide daily via SC injection for 4 weeks. PK samples will be collected on Day 1 and at week 4 to determine PK profile in BTHS patients weighing between 7 and 30kg.
In this Phase 1, open-label trial to evaluate the PK, safety, and tolerability of elamipretide, approximately 6 pediatric subjects with genetically confirmed BTHS weighing between 7 and 30 kg will be enrolled to receive daily dosing via SC injection for 4 weeks.
To characterize the PK of elamipretide, PK sampling will be conducted at Day 1 and Week 4. The study is intended to characterize PK and safety across a broader range of body weights that haven't been studied in prior trials.
Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SC injection daily
Drug: Elamipretide
SC injection daily
Also known as: FORZINITY
Maximum plasma concentration of elamipretide and its metabolites
Characterization of the maximum plasma concentration (Cmax) of elamipretide and its metabolites utilizing population PK modeling.
Time frame: 24 hours
Area under the plasma concentration time curve from 0 to 24 hours
Characterization of the area under the plasma concentration time curve from 0 to 24 hours of elamipretide and its metabolites (AUC0-24) utilizing population PK modeling.
Time frame: 24 hours
Safety Assessments: Adverse Events and Serious Adverse Events
The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) coded to system organ class and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) from baseline through 4 weeks. Report the # of subjects with adverse events and incidence and severity of such adverse events (AEs)
Time frame: 4 weeks
Change from baseline of Clinical Hematology
Change from baseline in clinical hematology utilizing descriptive statistics of change relative to baseline and shift tables to show number of subjects who are low, normal, high at baseline verses week 4.
Time frame: 4 Weeks
Change in Clinical Chemistry from Baseline
Change from baseline in Clinical Chemistry utilizing descriptive statistics of change relative to baseline and shift tables to show number of subjects who are low, normal, high at baseline verses week 4.
Time frame: 4 weeks
Change in 12 Lead Electrocardiogram ECG QT Interval from Baseline
Change in findings of 12 Lead Electrocardiogram ECG QT Interval from baseline
Time frame: 4 weeks
Change in 12 Lead Electrocardiogram ECG heart rate from Baseline
Change in 12 Lead Electrocardiogram ECG heart Rate from Baseline
Time frame: 4 weeks
Change in Vital Signs from Baseline: Temperature
Change in temperature measure (Fahrenheit or Celsius) from baseline to week 4
Time frame: 4 weeks
Change in Vital Signs from Baseline: Respiratory Rate
Change in respiratory rate (breaths per minute) from baseline to week 4
Time frame: 4 weeks
Change in Vital Signs from Baseline: Blood Pressure
Change in resting (5 minutes) Blood Pressure (mm Hg) from baseline to week 4
Time frame: 4 weeks
Change in Vital Signs from Baseline: heart rate
Change in Heart Rate (beats per minute) from baseline to week 4
Time frame: 4 weeks
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for May 2027, 6 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elamipretide
Barth Syndrome
Stealth BioTherapeutics Inc. →